The incidence and trends of proteinuria, azotemia and hypertension in cats receiving toceranib phosphate
The incidence of proteinuria, renal azotemia and hypertension in cats treated with toceranib for neoplasia appears to be low. Toceranib may be a viable treatment option even in cats with pre-existing proteinuria or renal disease, with careful monitoring of trends recommended.
Authors
- Valerie MacDonald‐Dickinson (ORCID: https://orcid.org/0009-0005-8255-9194)
- Arata Matsuyama (ORCID: https://orcid.org/0000-0002-8314-5656)
- Kimberly Y. Williams (ORCID: https://orcid.org/0009-0006-8388-8181)
Institutions
- University of Saskatchewan (CA)
Publication Details
- Journal
- Journal of Feline Medicine and Surgery
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1177/1098612x241266418
- Citations
- 1
- Primary Topic
- Veterinary Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42